Our studies demonstrate that administration of a DNA-PKi in conjunction with immune adjuvants strongly induced a clinically relevant IFN-γ and inflammatory gene signature favoring tumor antigen processing and presentation and T cell recruitment. This evidence concerns the gene IFNG and neoplasm.